Target Information

Target General Information

Top

Target ID

T96721 (Former ID: TTDS00339)

Target Name

Vascular endothelial growth factor (VEGF)

Synonyms

Vascular endothelial cell growth factor

Click to Show/Hide

Gene Name

NO-GeName

Target Type

Successful target

[1]

Disease

[+] 1 Target-related Diseases

Retinopathy [ICD-11: 9B71]

BioChemical Class

Growth factor

UniProt ID

VEGFA_HUMAN ; VEGFB_HUMAN ; VEGFC_HUMAN ; VEGFD_HUMAN

Drugs and Modes of Action

Top

Clinical Trial Drug(s)

[+] 6 Clinical Trial Drugs

PF-06439535

Drug Info

Phase 3

Non-small-cell lung cancer

[9]

Squalamine

Drug Info

Phase 3

Solid tumour/cancer

[10]

ALG-1001

Drug Info

Phase 2

Diabetic macular edema

[13]

TG100801

Drug Info

Phase 2

Macular degeneration

[14]

ABT-165

Drug Info

Phase 1

Solid tumour/cancer

[19]

NM-3

Drug Info

Phase 1

Solid tumour/cancer

[20]

Mode of Action

[+] 2 Modes of Action

Modulator

[+] 2 Modulator drugs

Squalamine

Drug Info

[22]

ALG-1001

Drug Info

[23]

Inhibitor

[+] 4 Inhibitor drugs

TG100801

Drug Info

[24]

ABT-165

Drug Info

[19]

NM-3

Drug Info

[25]

BIBF100

Drug Info

[26]

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Target Poor or Non Binders

Top

Target Poor or Non Binders

Target Poor or Non Binders Info

Target-Related Models and Studies

Top

Target Validation

Target Validation Info

References

Top

REF 1

Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.

REF 2

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019

REF 3

ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.

REF 4

ClinicalTrials.gov (NCT04603937) A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLIMMER). U.S. National Institutes of Health.

REF 5

ClinicalTrials.gov (NCT02810457) Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA). U.S. National Institutes of Health.

REF 6

ClinicalTrials.gov (NCT05378867) A Phase 3, Multicenter, Randomized and Double-blind Study Assessing the Interchangeability Between TRS003 and China-approved Bevacizumab? (Also Called China-approved Avastin) For First-Line Treatment of Patients With Metastatic Colorectal Cancer (CRC). U.S.National Institutes of Health.

REF 7

ClinicalTrials.gov (NCT04633564) Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin?, in the First-line Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer. U.S.National Institutes of Health.

REF 8

ClinicalTrials.gov (NCT04450329) A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB15 (Proposed Aflibercept Biosimilar) and Eylea? in Subjects With Neovascular Age-related Macular Degeneration. U.S.National Institutes of Health.

REF 9

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 10

ClinicalTrials.gov (NCT00139282) A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration. U.S. National Institutes of Health.

REF 11

ClinicalTrials.gov (NCT03368859) A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab. U.S. National Institutes of Health.

REF 12

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035470)

REF 13

Clinical pipeline report, company report or official report of Allegro Ophthalmics.

REF 14

ClinicalTrials.gov (NCT00509548) Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD. U.S. National Institutes of Health.

REF 15

ClinicalTrials.gov (NCT02475109) Study of Topical Ocular PAN-90806 in PDR.

REF 16

ClinicalTrials.gov (NCT03972150) A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer. U.S. National Institutes of Health.

REF 17

ClinicalTrials.gov (NCT03292783) This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001. U.S. National Institutes of Health.

REF 18

ClinicalTrials.gov (NCT04567303) A Three-Part, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Zifibancimig Following Intravitreal Administration of Multiple Ascending Doses and Continuous Delivery From the Port Delivery in Patients With Neovascular Age-Related Macular Degeneration. U.S.National Institutes of Health.

REF 19

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 20

ClinicalTrials.gov (NCT00046696) A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health.

REF 21

National Cancer Institute Drug Dictionary (drug id 43234).

REF 22

Clinical pipeline report, company report or official report of Ohr Pharmaceutical.

REF 23

Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070.

REF 24

Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.

REF 25

2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006 May;55(5):1232-42.

REF 26

Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Yuzong CHEN

Prof. Feng ZHU